fludarabine,cyclophosphamide,allo-316,allo-647
allogene therapeutics
['traverse', 'renal,(-adrenal)', 'rcc,(-irccs),(-srcc),(-urcc)']
encouraging response rates resulting from car t cell therapy for patients with metastatic clear cell renal cell carcinoma (ccrcc), said our dr. samer srour at #aacr23 this morning, presenting results of the ongoing traverse trial. 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789